Advertisement

21st International AIDS Conference (AIDS 2016)

News

Most Study Participants Were Satisfied With a New Long-Acting Injectable HIV Regimen

September 13, 2016

A follow-up analysis from LATTE-2 showed that most participants generally favored an injectable HIV regimen to taking daily pills, with many stating that it helped with stigma.

An analysis was presented from 39 in-depth interviews of 27 participants (2 of whom were women) and 12 clinicians of patient experiences with injections. Most rated their satisfaction with getting intramuscular injections every 4 or 8 weeks over at least 32 weeks of treatment as a 5 or 6 on a 6-point scale.

Average age was 37 years and most participants were gay men. Almost all reported some level of side effects with the injected regimen: 82% mild and 17% moderate injection site reactions that included soreness, pain, swelling and nodules usually lasting 1-2 days and at most 7 days. Other side effects included fever, tiredness, headache and rash reported by 4% or fewer people.

Some participants said the injections were simpler and more convenient than daily dosing and helped with their confidentiality. Participants generally preferred the injections to taking daily pills (~80%) and would like to continue on them (~85%). However, some were concerned with the number of clinic visits to get the injections, especially for those injected every 4 weeks.

The 12 clinicians were concerned about the issues that injections may pose in the context of patients missing visits, managing side effects and resistance. More research will be needed to identify who would be good candidates for injected regimens.


Source

D Kerrigan, et al. Experiences with long-acting injectable ART: ... (LATTE-2). 2016 International AIDS Conference, Durban, South Africa. Abstract THAB0204.


Related Stories

Dual Long-Acting Cabotegravir Plus Rilpivirine Injections: 48-Week Results From LATTE-2
Undetectable With Long-Acting, User-Friendly Injectable HIV Medications
Really Rapid Review -- AIDS 2016, Durban



This article was provided by Project Inform. It is a part of the publication The 21st International AIDS Conference (AIDS 2016). Visit Project Inform's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.